Deciphera CEO on tackling cancer drug resistance

December 16, 2016 Christoph Graener

 

Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals’ CEO Michael Taylor about the company’s cell-signaling technology, based on a clinical pipeline of kinase inhibitors. Taylor also explains the company’s strategy of addressing drug resistance in cancer.
By simultaneously blocking multiple cancer signaling mechanisms, Deciphera believes its therapies can control drug-resistant mutations while improving therapeutic potency, durability, and selectivity. Its pipeline includes three Phase I assets and a preclinical program.



Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Taylor – CEO, Deciphera Pharmaceuticals

 

Previous Article
Promethera extends series C on interest from Asian investors

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks about developing innovative therapies for the ...

Next Article
Inositec CEO on 2017 financing plans
Inositec CEO on 2017 financing plans

Inositec is developing innovative new drugs using its proprietary Inositune technology to adjust the proper...